Welcome to China Oncology,
China Oncology ›› 2022, Vol. 32 ›› Issue (4): 357-362.doi: 10.19401/j.cnki.1007-3639.2022.04.009
• Short Article • Previous Articles Next Articles
ZHOU Changshuai1(
)(
), YANG Yuechao1, CUI Huanhuan1, CHEN Lei1, CHEN Xin1, HAO Bin1, TONG Tong2, CAO Yiqun1()()
Received:2022-01-19
Revised:2022-02-20
Online:2022-04-30
Published:2022-05-07
Contact:
CAO Yiqun
E-mail:zhoucs1682@163.com;gem23@163.com
CLC Number:
ZHOU Changshuai, YANG Yuechao, CUI Huanhuan, CHEN Lei, CHEN Xin, HAO Bin, TONG Tong, CAO Yiqun. Prognostic factor analysis of surgical treatment for cerebellar metastases in 36 patients[J]. China Oncology, 2022, 32(4): 357-362.
Tab. 1
Clinicopathological features of 36 patients with cerebellar metastases"
| Factors | n=36 |
|---|---|
| Age/year | 58.75±8.99 |
| Female | 16 (44.44%) |
| Extracranial metastasis | 23 (63.89%) |
| Lesions | |
| 1 | 18 (50.00%) |
| 2 | 10 (27.78%) |
| ≥3 | 8 (22.22%) |
| Diameter D/cm | |
| ≥3 | 24 (66.67%) |
| <3 | 12 (33.33%) |
| Location | |
| Cerebellar metastases | 19 (52.78%) |
| Combined supratentorial metastases | 17 (47.22%) |
| Peritumoral edema | |
| Light | 16 (44.44%) |
| Moderate | 11 (30.56%) |
| Severe | 9 (25.00%) |
| Primary tumor | |
| Lung cancer | 19 (52.78%) |
| Breast cancer | 7 (19.44%) |
| Colorectal cancer | 4 (11.11%) |
| Gynecological tumor | 2 (5.56%) |
| Melanoma | 2 (5.56%) |
| Renal carcinoma | 1 (2.78%) |
| Pancreatic cancer | 1 (2.78%) |
| Ki-67 proliferation index | |
| <50% | 15 (41.67%) |
| ≥50% | 21 (58.33%) |
| Postoperative targeted therapy | 18 (50.00%) |
| Postoperative radiotherapy | 20 (55.56%) |
Fig. 1
Left cerebellar metastasis A: Preoperative; B: Postoperative."
Tab. 2
Univariate and multivariate Cox regression analysis of 36 cases of cerebellar metastases"
| Characteristics | Case (n=36) | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|
| Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value | ||
| Age (≥65 years) | 9 | 1.838 (0.727-4.646) | 0.198 | ||
| Gender (male) | 20 | 1.854 (0.747-4.606) | 0.183 | ||
| Extracranial metastasis | 23 | 1.696 (0.656-4.384) | 0.276 | ||
| KPS score≥70 | 24 | 0.767 (0.316-1.865) | 0.559 | ||
| Diameter ≥3 cm | 24 | 0.739 (0.287-1.904) | 0.531 | ||
| Multiple lesions (≥3) | 8 | 3.393 (1.371-8.400) | 0.008 | 2.079 (0.516-8.375) | 0.303 |
| Combined supratentorial metastases | 17 | 2.334 (0.949-5.739) | 0.065 | 1.517 (0.432-5.332) | 0.515 |
| Peritumoral edema (severe) | 9 | 0.524 (0.166-1.659) | 0.272 | ||
| Postoperative radiotherapy | 20 | 0.262 (0.106-0.648) | 0.004 | 0.040 (0.008-0.196) | <0.001 |
| Postoperative targeted therapy | 18 | 0.321 (0.122-0.846) | 0.022 | 0.178 (0.052-0.602) | 0.006 |
| Ki-67 proliferation index ≥50% | 21 | 3.543 (1.255-10.002) | 0.017 | 3.772 (1.067-13.336) | 0.039 |
Fig. 2
Kaplan-Meier survival analysis of prognostic factors after cerebellar metastases resection A: Ki-67 index; B: Postoperative targeted therapy; C: Postoperative radiotherapy; D: Number of lesions."
Fig. 3
Kaplan-Meier survival analysis of peritumoral edema of cerebellar metastases"
| [1] |
SUH J H,, KOTECHA R,, CHAO S T, et al. Current approaches to the management of brain metastases[J]. Nat Rev Clin Oncol, 2020, 17(5): 279-299.
doi: 10.1038/s41571-019-0320-3 |
| [2] |
YOSHIDA S,, TAKAHASHI H. Cerebellar metastases in patients with cancer[J]. Surg Neurol, 2009, 71(2): 184-187; discussion187.
doi: 10.1016/j.surneu.2007.10.010 |
| [3] |
LEE K J,, JOO W I,, RHA H K, et al. Peritumoral brain edema in meningiomas: correlations between magnetic resonance imaging, angiography, and pathology[J]. Surg Neurol, 2008, 69(4): 350-355; discussion355.
doi: 10.1016/j.surneu.2007.03.027 |
| [4] |
CHAICHANA K L,, RAO K,, GADKAREE S, et al. Factors associated with survival and recurrence for patients undergoing surgery of cerebellar metastases[J]. Neurol Res, 2014, 36(1): 13-25.
doi: 10.1179/1743132813Y.0000000260 |
| [5] | 盛舒言,, 胡瑛. 脑转移瘤免疫相关疗效评价标准的研究进展[J]. 中国肺癌杂志, 2021, 24(2): 124-130. |
| SHENG S Y,, HU Y. Ongoing evaluation of immune-related response assessment in brain metastases[J]. Chin J Lung Cancer, 2021, 24(2): 124-130. | |
| [6] |
GASPAR L,, SCOTT C,, ROTMAN M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials[J]. Int J Radiat Oncol Biol Phys, 1997, 37(4): 745-751.
doi: 10.1016/S0360-3016(96)00619-0 |
| [7] |
SPERDUTO P W,, BERKEY B,, GASPAR L E, et al. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1 960 patients in the RTOG database[J]. Int J Radiat Oncol Biol Phys, 2008, 70(2): 510-514.
doi: 10.1016/j.ijrobp.2007.06.074 |
| [8] |
SPERDUTO P W,, CHAO S T,, SNEED P K, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4 259 patients[J]. Int J Radiat Oncol Biol Phys, 2010, 77(3): 655-661.
doi: 10.1016/j.ijrobp.2009.08.025 |
| [9] | 李建峰,, 崔凯,, 刘荣举. 37例手术治疗小脑转移瘤预后因素分析[J]. 中国微侵袭神经外科杂志, 2019, 24(10): 456-459. |
| LI J F,, CUI K,, LIU R J. Analysis of prognostic factors of surgery for cerebellar metastasis in 37 patients[J]. Chin J Minim Invasive Neurosurg, 2019, 24(10): 456-459. | |
| [10] |
SCHACKERT G,, LINDNER C,, PETSCHKE S, et al. Retrospective study of 127 surgically treated patients with multiple brain metastases: indication, prognostic factors, and outcome[J]. Acta Neurochir (Wien), 2013, 155(3): 379-387.
doi: 10.1007/s00701-012-1606-8 |
| [11] | 周先申,, 万经海. 多发脑转移瘤手术指征及综合治疗探讨[J]. 中国临床医生杂志, 2017, 45(4): 69-72. |
| ZHOU X S,, WAN J H. Surgical indications and comprehensive treatment of multiple brain metastases[J]. Chin J Clin, 2017, 45(4): 69-72. | |
| [12] |
INARI H,, SUGANUMA N,, KAWACHI K, et al. Clinicopathological and prognostic significance of Ki-67 immunohistochemical expression of distant metastatic lesions in patients with metastatic breast cancer[J]. Breast Cancer, 2017, 24(6): 748-755.
doi: 10.1007/s12282-017-0774-z |
| [13] |
SAAD A G,, YEAP B Y,, THUNNISSEN F B, et al. Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma[J]. Cancer, 2008, 113(8): 2129-2138.
doi: 10.1002/cncr.23826 |
| [14] |
BUBB R S,, KOMAKI R,, HACHIYA T, et al. Association of Ki-67, p53, and bcl-2 expression of the primary non-small cell lung cancer lesion with brain metastatic lesion[J]. Int J Radiat Oncol Biol Phys, 2002, 53(5): 1216-1224.
doi: 10.1016/S0360-3016(02)02861-4 |
| [15] |
SPANBERGER T,, BERGHOFF A S,, DINHOF C, et al. Extent of peritumoral brain edema correlates with prognosis, tumoral growth pattern, HIF1a expression and angiogenic activity in patients with single brain metastases[J]. Clin Exp Metastasis, 2013, 30(4): 357-368.
doi: 10.1007/s10585-012-9542-9 |
| [16] | 王月坤,, 刘磊,, 陈琬琦, 等. 脑转移瘤患者单纯手术治疗与手术联合术后脑部放疗对比分析[J]. 中国现代神经疾病杂志, 2021, 21(3): 162-169. |
| WANG Y K,, LIU L,, CHEN W Q, et al. Comparison of neurosurgery combined brain radiotherapy versus neurosurgery alone for patients with brain metastases[J]. Chin J Contemp Neurol Neurosurg, 2021, 21(3): 162-169. | |
| [17] |
BROWN P D,, BALLMAN K V,, CERHAN J H, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2017, 18(8): 1049-1060.
doi: 10.1016/S1470-2045(17)30441-2 |
| [18] |
SHAH P P,, FRANKE J L,, MEDIKONDA R, et al. Mutation status and postresection survival of patients with non-small cell lung cancer brain metastasis: implications of biomarker-driven therapy[J]. J Neurosurg, 2022, 136(1): 56-66.
doi: 10.3171/2020.10.JNS201787 |
| [19] |
WANG H J,, WANG Z Q,, ZHANG G W, et al. Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations[J]. Cancer Med, 2020, 9(2): 487-495.
doi: 10.1002/cam4.2706 |
| [20] | MILLER J A,, KOTECHA R,, AHLUWALIA M S, et al. The impact of tumor biology on survival and response to radiation therapy among patients with non-small cell lung cancer brain metastases[J]. Pract Radiat Oncol, 2017, 7(4): e263-e273. |
| [21] |
GADGEEL S,, PETERS S,, MOK T, et al. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer: CNS efficacy results from the ALEX study[J]. Ann Oncol, 2018, 29(11): 2214-2222.
doi: 10.1093/annonc/mdy405 |
| [22] |
FIGURA N B,, RIZK V T,, MOHAMMADI H, et al. Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy[J]. Breast Cancer Res Treat, 2019, 175(3): 781-788.
doi: 10.1007/s10549-019-05170-7 |
| [23] |
FABI A,, ALESINI D,, VALLE E, et al. T-DM1 and brain metastases: clinical outcome in HER2-positive metastatic breast cancer[J]. Breast, 2018, 41: 137-143.
doi: 10.1016/j.breast.2018.07.004 |
| [24] | 张佳玲,, 张凤春,, 徐迎春. 乳腺癌脑转移系统治疗的研究进展[J]. 上海交通大学学报(医学版), 2021, 41(5): 671-677. |
| ZHANG J L,, ZHANG F C,, XU Y C. Research progress in the systemic treatment for breast cancer with brain metastasis[J]. J Shanghai Jiao Tong Univ Med Sci, 2021, 41(5): 671-677. | |
| [25] | 邱娴,, 胡良运,, 周敏, 等. 小剂量贝伐珠单抗治疗肺癌复发脑转移瘤伴难治性瘤周水肿的疗效分析[J]. 中华转移性肿瘤杂志, 2019, 2(4): 25-30. |
| [26] | 杨泽兴,, 王宏伟. 贝伐珠单抗治疗脑转移瘤瘤周水肿的短期疗效观察[J]. 中华神经外科杂志, 2020, 36(8): 837-840. |
| YANG Z X,, WANG H W. Short term efficacy of bevacizumab in the treatment of peritumoral edema of brain metastases[J]. Chin J Neurosurg, 2020, 36(8): 837-840. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
沪ICP备12009617
Powered by Beijing Magtech Co. Ltd
